1300PD - Impact of co-occurring genomic alterations on overall survival of BRAF V600E and non-V600E mutated NSCLC patients: results of the Network Genomic M...

Date 10 September 2017
Event ESMO 2017 Congress
Session NSCLC, metastatic
Topics Cytotoxic agents
Cancers in Adolescents and Young Adults (AYA)
Thoracic malignancies
Personalised/Precision medicine
Non-small-cell lung cancer
Basic Principles in the Management and Treatment (of cancer)
Biological therapy
Presenter Anna Kron
Citation Annals of Oncology (2017) 28 (suppl_5): v460-v496. 10.1093/annonc/mdx380
Authors A. Kron1, R. Riedel1, S. Michels1, J. Fassunke2, S. Merkelbach-Bruse2, M. Scheffler1, L. Nogova1, R. Fischer1, F. Ueckeroth2, D. Abdulla1, F. Kron1, B. Pauli1, B. Kaminsky3, J. Braess4, U. Graeven5, C. Grohe6, S. Krueger7, R. Büttner2, J. Wolf1
  • 1Department I Of Internal Medicine, Lung Cancer Group Cologne, University Hospital of Cologne, 50937 - Cologne/DE
  • 2Institute Of Pathology, University Hospital of Cologne, 50937 - Cologne/DE
  • 3Department Of Pneumology, Bethanien Hospital, 42699 - Solingen/DE
  • 4Department Of Oncology And Haematology, St. John of God's Hospital, 93047 - Regensburg/DE
  • 5Department Of Oncology And Haematology, Kliniken Maria Hilf GmbH, 41063 - Mönchengladbach/DE
  • 6Department Of Respiratory Diseases, Universitätsmedizin Charite, Berlin/DE
  • 7Department Of Pneumology, Florence Nightingale-Krankenhaus, Düsseldorf/DE



Activating BRAF mutations are found in 1-3% of lung adenocarcinomas. Treatment with a combination of a BRAF- and a MEK-inhibitor is now the approved standard therapy for V600E mutated patients. The molecular co-alterations that drive the heterogeneity of BRAF mutated lung cancer patients (pts) are poorly characterized by the lack of multiplex diagnostics results. Frequently used single gene tests are unable to detect co-occurring mutations and their mutual impact on overall survival. The Network Genomic Medicine (NGM) performs high sensitive next generation sequencing (NGS) based diagnostics on a central platform in Cologne for inoperable lung cancer pts in Germany.


The NGS panel used in NGM consists of 17 genes to cover potentially targetable aberrations and is run on Illumina (MySeq) platform. In 2016, we have started the retrospective evaluation of BRAF mutated pts with available clinical data and given consent who had received NGS-based molecular diagnostics. In particular, we have focused on BRAF V600E and non-V600E mutated lung cancer pts with and without co-occurring mutations: their frequency, significance and impact on overall survival.


We have analyzed 174 pts (V600E=55 pts, non-V600E=119 pts) with eligible clinical data. Co-occurring mutations were detected in 121 BRAF mutated pts (70%). The most frequent co-alteration was found in TP53 for 89 pts (74%). Regardless of treatment regime, BRAF mutated lung cancer pts without co-alterations seem to have a better overall survival (OS) with 15 versus 13 month (p = 0.463), same data for the TP53 co-mutated pts (p = 0.449). Likewise, non-targeted treatment of V600E mutation seems to be a negative prognostic factor with OS = 15 month versus 22 month in non-V600E mutated pts (p = 0.957).


We report for the first time to our knowledge the heterogeneity of BRAF mutated lung cancer pts in the largest cohort. This work provides evidence that co-occurring genomic alterations influence the overall survival of these pts and stresses the relevance of the multiplex genotyping. Further data including therapies, co-alterations in V600E and other clinicopathologic parameters will be provided.

Clinical trial identification

Legal entity responsible for the study

University Hospital of Cologne for the Network Genomic Medicine




All authors have declared no conflicts of interest.